

May 28, 2018

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Audited Financial Results for the Quarter and Year ended 31st March 2018.

The Board of Directors of the Company at its meeting held on 28th May 2018 has inter-alia, considered and approved the Audited Financial Results of the Company for the Quarter and Year ended 31st March 2018. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we enclose herewith the Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors and Declaration with regard to Auditor's Report with unmodified opinion.

The Board meeting commenced at 3.00 p.m and concluded at 7.00 p.m.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary



AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitriviham, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aubindoo.com

(Rs. In lakhs)

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2018

Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from operations					
(a) Net sales/ income from operations (refer note 3)	229,632	262,035	236,139	1,004,196	953,936
(b) Other operating income	5,840	6,593	5,870	26,119	24,185
Total revenue from operations	235,472	268,628	242,009	1,030,315	978,121
2 Other Income					
(a) Foreign exchange gain (net)	295	2,800	2,925	5,853	9,893
(b) Others	341	579	2,197	2,212	3,702
Total other Income	636	3,379	5,122	8,065	13,595
Total Income (1+2)	236,108	272,007	247,131	1,038,380	991,716
3 Expenses					
(a) Cost of materials consumed	119,149	124,149	111,978	489,327	460,419
(b) Purchase of stock-in-trade	42	160	500	372	1,121
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(9,049)	1,110	52	(33,418)	3,132
(d) Employee benefits expense	31,739	28,318	25,250	113,164	92,730
(e) Finance costs	1,741	1,321	906	5,289	4,516
(f) Depreciation and amortisation expense	9,155	9,028	7,338	35,483	28,617
(g) Other expenses	45,803	48,461	46,230	193,869	183,324
Total expenses	198,580	212,547	192,254	804,086	773,859
4 Profit before tax (1+2-3)	37,528	59,460	54,877	234,294	217,857
5 Tax expense	6,699	15,028	9,331	53,017	47,181
6 Net profit for the period (4-5)	30,829	44,432	45,546	181,277	170,676
7 Other Comprehensive income / (expense) - items that will not be reclassified to profit or loss (net of tax)	193	(137)	30	(218)	(561)
8 Total Comprehensive Income for the period (6+7)	31,022	44,295	45,576	181,059	170,115
9 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859
10 Other equity				992,399	837,759
11 Earnings per equity share of Re. 1 each (not annualised)					
(a) Basic	5.26	7.58	7.78	30.94	29.16
(b) Diluted	5.26	7.58	7.78	30.94	29.16

NOTES:

- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on May 28, 2018.
- Post implementation of Goods and Services Tax ('GST') with effect from July 1, 2017, revenues from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in the GST. Revenue from operations for the year ended March 31, 2018 includes excise duty upto June 30, 2017. Accordingly, revenue from operations for the quarter and year ended March 31, 2018 are not comparable with those of the previous periods presented.
- During the quarter i) Acrotech Biopharma LLC - Incorporated on January 5, 2018 ii) Aurovitaz Pharma (Taizhou) Ltd - Incorporated on January 29, 2018. iii) Aubindoo Pharma USA LLC - (Dissolved w.e.f March 31, 2018). iv) Farma APS - Prmooao de Medicamentos, Unipessoal Lda., (Dissolved w.e.f. January 25, 2018). v) Generis Mozambique, Lda (Dissolved w.e.f March 19, 2018). vi) Mer Medicamentos, Lda (Merged with Generis Farmaceutica SA effective April 1, 2018). vii) Aurovitaz, Unipessoal LDA (Merged with Generis Farmaceutica SA effective April 1, 2018). viii) Aubindoo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceutica SA effective April 1, 2018).
- The Company operates in only one segment viz., 'Pharmaceutical Products'.
- The Company has allotted 25,200 equity shares of Re.1/- (Rupee One only) on March 28, 2018 to the employees under Employee Stock option plan 2006. Consequent to the allotment, the paid-up share capital of Company has increased from 585,882,409 to 585,907,609 equity shares of Re.1/- each.
- Sales of standalone for current quarter include exports of Rs.188,309 lakhs (March 31, 2017: Rs. 198,698 lakhs).
- The figures of the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2018 and March 31, 2017 respectively and the unaudited published year to date figures upto December 31, 2017 and December 31, 2016 respectively, being the date of the end of the third quarter of the financial year. The standalone results for the nine months ended December 31, 2017 and December 31, 2016 have been subjected to the limited review by the statutory auditors.
- Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan
Managing Director



Place: Hyderabad
Date : May 28, 2018

www.aubindoo.com



FOR IDENTIFICATION ONLY

Standalone Balance Sheet

(Rs. In lakhs)

Sl. No.	PARTICULARS	As at	As at
		31.03.2018	31.03.2017
		(Audited)	(Audited)
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	339,297	321,162
	Capital work-in-progress	110,023	87,831
	Intangible assets under development	4,375	2,867
	Financial assets		
	Investments	196,748	168,193
	Loans	1,326	4,636
	Other financial assets	9,641	8,075
	Non current tax assets (net)	8,260	5,795
	Deferred tax assets (net)	-	8
	Other non-current assets	11,594	13,390
	Non-Current assets	681,264	611,957
2	Current assets		
	Inventories	340,923	243,362
	Financial assets		
	Investments	2	2
	Trade receivables	447,744	377,363
	Cash and cash equivalents	24,590	3,363
	Loans	976	1,025
	Other financial assets	309	1,658
	Other current assets	83,992	63,561
	Current assets	898,536	690,334
	TOTAL - ASSETS	1,579,800	1,302,291
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,859
	Other equity	992,399	837,759
	Equity	998,258	843,618
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	-	11,890
	Provisions	3,360	2,086
	Deferred tax liability (net)	2,348	-
	Non-current liabilities	5,708	13,976
3	Current liabilities		
	Financial liabilities		
	Borrowings	365,383	275,127
	Trade payables	163,340	121,760
	Other financial liabilities	25,265	33,646
	Other current liabilities	14,392	8,014
	Provisions	7,454	6,150
	Current liabilities	575,834	444,697
	TOTAL EQUITY AND LIABILITIES	1,579,800	1,302,291



FOR IDENTIFICATION ONLY



B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Independent Auditor's Report on Annual Standalone Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To
Board of Directors of Aurobindo Pharma Limited

1. We have audited the accompanying annual standalone financial results of Aurobindo Pharma Limited ('the Company') for the year ended 31 March 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
2. These standalone financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results upto the end of the third quarter, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these standalone financial results based on our audit of the annual standalone financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.
3. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
4. Corresponding figures for the period/year ended 31 March 2017 included in the standalone financial results were audited by the predecessor auditor who expressed an unmodified opinion dated 29 May 2017.

Independent Auditor's Report on Annual Standalone Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Continued)

5. In our opinion and to the best of our information and according to the explanations given to us, these annual standalone financial results:
- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view of the net profit, other comprehensive income and financial information for the year ended 31 March 2018.

For **B S R & Associates LLP**
Chartered Accountants
Firm's Registration No: 116231 W/W-100024



Amit Kumar Agarwal
Partner
Membership No. 214198

Place: Hyderabad
Date: 28 May 2018

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurbindo.com

(Rs. In lakhs)

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2018

Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from operations					
(a) Net sales/ income from operations (refer note 4)	398,863	426,899	358,213	1,623,287	1,484,479
(b) Other operating income	6,046	6,712	5,950	26,697	24,507
Total revenue from operations	404,909	433,611	364,163	1,649,984	1,508,986
2 Other Income					
(a) Foreign exchange gain (net)	-	726	1,903	-	6,205
(b) Others	4,383	2,579	2,175	10,198	5,384
Total other Income	4,383	3,305	4,078	10,198	11,589
Total Income (1+2)	409,292	436,916	368,241	1,660,182	1,520,575
3 Expenses					
(a) Cost of materials consumed	142,779	138,371	127,942	562,937	518,492
(b) Purchase of stock-in-trade	46,673	44,283	34,769	160,588	155,854
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(22,505)	(904)	(12,430)	(48,251)	(30,920)
(d) Employee benefits expense	58,127	54,068	46,346	213,084	176,776
(e) Finance costs	2,472	1,886	1,428	7,771	6,672
(f) Foreign exchange loss (net)	1,592	-	-	1,676	-
(g) Depreciation and amortisation expense	15,663	13,808	10,005	55,797	42,763
(h) Other expenses	99,432	95,235	95,412	382,774	345,356
Total expenses	344,233	346,747	303,472	1,336,376	1,214,993
4 Profit before tax (1+2-3)	65,059	90,169	64,769	323,806	305,582
5 Share of profit of joint ventures, net of tax	56	11	168	314	502
6 Profit before tax (4+5)	65,115	90,180	64,937	324,120	306,084
7 Tax expense	12,239	30,694	11,715	81,828	75,964
8 Net profit for the period (6-7)	52,876	59,486	53,222	242,292	230,120
9 Non controlling interest	25	(15)	(23)	(26)	(47)
10 Net profit after taxes and non controlling Interest (8-9)	52,851	59,501	53,245	242,318	230,167
11 Other Comprehensive income/ (expense)					
i) items that will not be reclassified subsequently to profit or loss (net of tax)	196	(137)	40	(237)	(579)
ii) items that will be reclassified subsequently to profit or loss	10,184	(4,729)	(10,269)	15,191	(8,044)
Total other comprehensive Income	10,380	(4,866)	(10,229)	14,954	(8,623)
12 Total Comprehensive Income for the period (10+11)	63,231	54,635	43,016	257,272	221,544
13 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859
14 Other equity				1,162,183	931,332
15 Earnings per equity share of Re. 1 each (not annualised)					
(a) Basic	9.02	10.16	9.10	41.36	39.33
(b) Diluted	9.02	10.16	9.10	41.36	39.33

NOTES:

- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint Ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- The above consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on May 28, 2018.
- Post implementation of Goods and Services Tax ('GST') with effect from July 1, 2017, revenues from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in the GST. Revenue from operations for the year ended March 31, 2018 includes excise duty upto June 30, 2017. Accordingly, revenue from operations for the quarter and year ended March 31, 2018 are not comparable with those of the previous periods presented.
- During the year, Agile Pharma B.V., a step down subsidiary of the Company acquired Generis Farmacêutica SA and its subsidiaries viz. (i) Mer Medicamentos, Portugal (ii) Generis Phar Ulipessoal Lda, Portugal (iii) Farma APS - Prmocoa de Medicamentos, Unipessoal Lda., Portugal (iv) Generis Mozambique Lda, Mozambique. The above consolidated financial results for the current quarter and year ended March 31, 2018 includes the results of operations of the above entities from May 01, 2017. The corresponding figures for the previous periods are not comparable.
- During the quarter i) Acrotech Biopharma LLC - Incorporated on January 5, 2018 ii) Aurovitaz Pharma (Taizhou) Ltd - Incorporated on January 29, 2018. iii) Aurobindo Pharma USA LLC - (Dissolved w.e.f March 31, 2018). iv) Farma APS - Prmocoa de Medicamentos, Unipessoal Lda., (Dissolved w.e.f. January 25, 2018). v) Generis Mozambique, Lda (Dissolved w.e.f March 19, 2018). vi) Mer Medicamentos, Lda (Merged with Generis Farmaceuita SA effective April 1, 2018). vii) Aurovitaz, Unipessoal LDA (Merged with Generis Farmaceuita SA effective April 1, 2018). viii) Aurobindo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceuita SA effective April 1, 2018).
- The Company operates in only one segment viz., 'Pharmaceutical Products'.
- The figures of the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2018 and March 31, 2017 respectively and the unaudited published year to date figures upto December 31, 2017 and December 31, 2016 respectively, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended December 31, 2017 and December 31, 2016 have been subjected to the limited review by the statutory auditors.
- The Company has allotted 25,200 equity shares of Re.1/- (Rupee One only) on March 28, 2018 to the employees under Employee Stock option plan 2006. Consequent to the allotment, the paid-up share capital of Company has increased from 585,882,409 to 585,907,609 equity shares of Re.1/- each.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan
Managing DirectorPlace: Hyderabad
Date : May 28, 2018

www.aurobindo.com



FOR IDENTIFICATION ONLY

Consolidated Balance Sheet

(Rs. In lakhs)

Sl. No.	PARTICULARS	As at 31.03.2018	As at 31.03.2017
		(Audited)	(Audited)
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	473,656	408,305
	Capital work-in-progress	139,954	123,736
	Goodwill	81,654	40,630
	Other intangible assets	96,757	34,443
	Intangible assets under development	18,350	22,072
	Financial assets		
	Investments	31,151	24,585
	Loans	544	570
	Other financial assets	8,746	7,517
	Non current tax assets (net)	8,259	5,798
	Deferred tax assets (net)	15,880	16,776
	Other non-current assets	16,783	19,892
	Non-Current assets	891,734	704,324
2	Current assets		
	Inventories	585,842	433,054
	Financial assets		
	Investments	2	2
	Trade receivables	308,436	276,533
	Cash and cash equivalents	121,590	48,944
	Bank balances other than above	4,572	2,404
	Loans	1,019	1,089
	Other financial assets	79,420	75,765
	Current tax assets (net)	6,455	1,751
	Other current assets	111,449	81,076
	Current assets	1,218,785	920,618
	TOTAL ASSETS	2,110,519	1,624,942
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,859
	Other equity	1,162,183	931,332
	Non-controlling interest	182	208
	Equity	1,168,224	937,399
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	45,120	18,140
	Provisions	5,586	3,913
	Deferred tax liability (net)	23,528	4,930
	Non-current liabilities	74,234	26,983
3	Current liabilities		
	Financial liabilities		
	Borrowings	403,134	290,272
	Trade payables	262,743	215,470
	Other financial liabilities	51,000	46,938
	Other current liabilities	126,780	81,743
	Provisions	20,093	23,491
	Current tax liabilities	4,311	2,646
	Current liabilities	868,061	660,560
	TOTAL EQUITY AND LIABILITIES	2,110,519	1,624,942



FOR IDENTIFICATION ONLY



B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Independent Auditor's Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of Aurobindo Pharma Limited

1. We have audited the annual consolidated financial results of Aurobindo Pharma Limited ('the Holding Company') comprising its subsidiaries (together 'the Group') and joint ventures as listed in Annexure - 1 for the year ended 31 March 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in these consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date consolidated figures upto the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
2. These annual consolidated financial results have been prepared from annual consolidated financial statements and reviewed quarterly consolidated financial results upto the end of the third quarter which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such annual consolidated financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.
3. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
4. We did not audit the financial statements of 55 subsidiaries and 4 joint ventures included in the annual consolidated financial results, whose annual financial statements reflect total assets of Rs. 1,474,726 lakhs as at 31 March 2018 as well as the total revenue of Rs. 1,165,660 lakhs for the year ended 31 March 2018. The consolidated financial results also include the Group's share of net profit (and other comprehensive income) of Rs. 247 lakhs for the year ended 31 March 2018 in respect of four joint ventures. These annual financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the annual consolidated financial results, to the extent they have been derived from such annual financial statements is based solely on the report of such other auditors.



Independent Auditor's Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)


Certain of these subsidiaries and a joint venture are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial statements of such subsidiaries and the joint ventures located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries and a joint venture located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and audited by us. Our opinion is not modified in respect of this matter.

5. Corresponding figures for the period/year ended 31 March 2017 included in the consolidated financial results were audited by the predecessor auditor who expressed an unmodified opinion dated 29 May 2017.
6. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate financial statements and on other information of the subsidiaries and joint ventures, these annual consolidated financial results:
 - (i) include the annual financial results of the entities listed in Annexure - 1;
 - (ii) have been presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (iii) give a true and fair view of the consolidated net profit and other comprehensive income and other financial information for the year ended 31 March 2018.

For B S R & Associates LLP

Chartered Accountants

Firm's Registration No: 116231 W/W-100024



Amit Kumar Agarwal

Partner

Membership No. 214198

Place: Hyderabad

Date: 28 May 2018

Independent Auditor's Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)

Annexure I

List of subsidiaries and joint ventures

S.No.	Component Name	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary
9	Natrol LLC	USA	Subsidiary
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Aurobindo Pharma USA LLC (dissolved w.e.f. 31 March 2018)	USA	Subsidiary
14	Auro AR LLC	USA	Subsidiary
15	Auro Vaccines LLC	USA	Subsidiary
16	Auro Logistics LLC (w.e.f. 28 April 2017)	USA	Subsidiary
17	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
18	Helix Healthcare B.V.	Netherlands	Subsidiary
19	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
20	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
21	Novagen Pharma (Pty) Limited	South Africa	Joint venture
22	Auro Pharma Inc.	Canada	Subsidiary
23	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
24	Auro Healthcare (Nigeria) Limited	Nigeria	Subsidiary
25	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
26	Aurobindo Ilac Sanayi Ve Ticaret Limited Sirketi (liquidated w.e.f. 31 October 2017)	Turkey	Subsidiary
27	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
28	Agile Pharma B.V.	Netherlands	Subsidiary
29	Arrow Generiques SAS	France	Subsidiary
30	1980 Puren Pharma GmbH (formerly Actavis Management GmbH)	Germany	Subsidiary
31	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary
32	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Subsidiary
33	Aurobindo Pharma B.V. (formerly known as Actavis B.V.)	Netherlands	Subsidiary
34	Aurex B.V. (formerly known as Pharmacin B.V.)	Netherlands	Subsidiary

AA

Independent Auditor's Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)

Annexure I (continued)

List of subsidiaries and joint ventures

S.No.	Component Name	Country	Relationship
35	Aurobindo Pharma GmbH	Germany	Subsidiary
36	Aurobindo Pharma (Portugal) Unipessoal Limitada	Portugal	Subsidiary
37	Laboratorios Aurobindo S.L.	Spain	Subsidiary
38	Aurobindo Pharma (Italia) S.r.l	Italy	Subsidiary
39	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
40	Aurovitas, Unipessoal LDA	Portugal	Subsidiary
41	Pharmacin B.V. (formerly known as Aurex B.V.)	Netherlands	Subsidiary
42	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
43	APL Swift Services (Malta) Limited	Malta	Subsidiary
44	Milpharm Limited	United Kingdom	Subsidiary
45	Aurovitas Pharma Polska	Poland	Subsidiary
46	Generis Farmaceutica S.A (w.e.f. 1 May 2017)	Portugal	Subsidiary
47	Mer Medicamentos, Lda. (w.e.f. 1 May 2017)	Portugal	Subsidiary
48	Generis Phar, Unipessoal Lda. (w.e.f. 1 May 2017)	Portugal	Subsidiary
49	Farma APS - Promoção de Medicamentos, Unipessoal Lda. (w.e.f. 1 May 2017, dissolved w.e.f. 25 January 2018)	Portugal	Subsidiary
50	Generis MZ, Lda. (w.e.f. 1 May 2017, dissolved w.e.f. 19 March 2018)	Mozambique	Subsidiary
51	Aurobindo Pharma Saudi Arabia Limited Company (w.e.f. 8 May 2017)	Saudi Arabia	Subsidiary
52	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
53	Hyacinths Pharma Private Limited	India	Subsidiary
54	Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd)	India	Joint Venture(w.e.f. 30 November 2017)
55	AuroZymes Limited	India	Subsidiary
56	Curepro Parenterals Limited	India	Subsidiary
57	Eugia Pharma Specialities Limited	India	Joint venture
58	Tergene Biotech Private Limited	India	Joint venture
59	Auro Pharma India Private Limited (w.e.f. 20 December 2017)	India	Subsidiary
60	Aurovitas Pharma Ceska republika s.r.o (w.e.f. 23 December 2017)	Czech Republic	Subsidiary
61	Aurovitas Pharma (Taizhou) Ltd (w.e.f. 29 January 2018)	China	Subsidiary
62	Acrotech Biopharma LLC (w.e.f. 5 January 2018)	USA	Subsidiary

May 28, 2018


To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Declaration pursuant to Regulation 52(3)(a) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

We hereby confirm and declare that the Statutory Auditors of the Company, M/s. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2018 with unmodified opinion.

For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary

